Nils Feltelius
YOU?
Author Swipe
View article: SARS-CoV-2 vaccination and myositis in Norway and Sweden
SARS-CoV-2 vaccination and myositis in Norway and Sweden Open
Objective The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. Methods We …
View article: Non‐steroidal anti‐inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high‐use populations
Non‐steroidal anti‐inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high‐use populations Open
Background Data on the association between non‐steroidal anti‐inflammatory drugs (NSAIDs) and kidney cancer (KC) are conflicting. This study aimed to evaluate this association in the general population and in patients with extensive NSAID …
View article: Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines
Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines Open
Background: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain. Methods: Pati…
View article: Federated analyses of multiple data sources in drug safety studies
Federated analyses of multiple data sources in drug safety studies Open
Purpose Studies of rare side effects of new drugs with limited exposure may require pooling of multiple data sources. Federated Analyses (FA) allow real‐time, interactive, centralized statistical processing of individual‐level data from di…
View article: The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE)
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE) Open
Background: The coronavirus disease 2019 (COVID-19) vaccines have been rapidly implemented in national vaccination programs world-wide after accelerated approval processes. The large population exposure achieved in very short time requires…
View article: Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision Open
Objectives To compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on r…
View article: Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice Open
Objective To estimate the occurrence and relative risks of first-ever-incident non-cutaneous cancer overall and for 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment star…
View article: Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study Open
Risks of severe COVID-19-related outcomes were increased among patients with IJDs, but risk increases were also seen for non-COVID-19 morbidity. Overall absolute and excess risks are low and the level of risk increases are largely proporti…
View article: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register Open
Objectives Current guidelines rank abatacept, rituximab, tocilizumab and TNF-inhibitors (TNFi) as having equal effectiveness for the treatment of RA, at least as second line therapies. These recommendations are mainly based on meta-analysi…
View article: Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective
Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective Open
Aim: The aim of this study was to describe content and procedures in some selected Swedish health care quality registries (QRs) of relevance to regulatory decision-making. Methods: A workshop was organized with participation of seven Swedi…
View article: Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective
Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective Open
Aim: The aim of this study was to describe content and procedures in some selected Swedish health care quality registries (QRs) of relevance to regulatory decision-making. Methods: A workshop was organized with participation of seven Swedi…
View article: Response to letter from Lars Andersson
Response to letter from Lars Andersson Open
Dear Sir, We appreciate the possibility to comment on the new letter from Lars Andersson in this issue, entitled ‘Hidden authority study data have come to light: besides narcolepsy the swine influenza vaccine Pandemrix caused type 1 diabet…